[The examinations for diffuse lung diseases]

Area of Science:

• Pulmonology and Respiratory Medicine
• Medical Diagnostics

Background:

• Diffuse lung diseases present as widespread abnormalities on chest X-rays, encompassing various conditions like infections, neoplasms, and idiopathic pulmonary fibrosis (IPF).
• IPF is a significant respiratory disease characterized by its frequency and challenging treatment.
• Diagnosis of IPF integrates respiratory function tests, high-resolution computed tomography (HRCT) findings, and histopathological evaluation, with usual interstitial pneumonia (UIP) pattern being crucial.

Observation:

• Standard serum examinations, including angiotensin-converting enzyme and anti-nuclear antibodies, are primarily used to exclude other diffuse lung diseases.
• While surfactant protein D (SP-D) and KL-6 show potential for monitoring disease activity, their lack of elevation in early IPF limits their diagnostic utility.
• Currently, no definitive serum examinations exist for IPF diagnosis, therapeutic effect determination, or prognosis assessment.

Findings:

• The established diagnostic criteria for IPF involve a combination of clinical, radiological (HRCT), and histopathological assessments.
• Existing biomarkers like SP-D and KL-6 are not consistently elevated in early-stage IPF, hindering their application in initial diagnosis.
• There is a significant gap in reliable and easily accessible serum-based diagnostic and prognostic markers for IPF.

Implications:

• The absence of definitive serum markers necessitates the continued reliance on invasive procedures like surgical lung biopsy for IPF diagnosis.
• Improved diagnostic and prognostic tools, potentially including genetic markers, are essential for effective patient management and treatment strategies for IPF.
• Further research into novel, non-invasive biomarkers is critical to advance the clinical management of idiopathic pulmonary fibrosis.